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ABSTRACT: Cellular membranes are, in general, impermeable to macromolecules (herein
referred to as macrodrugs, e.g., recombinant protein, expression plasmids, or mRNA), which is a
major barrier for clinical translation of macrodrug-based therapies. Encapsulation of macro-
molecules in lipid nanoparticles (LNPs) can protect the therapeutic agent during transport
through the body and facilitate the intracellular delivery via a fusion-based pathway. Furthermore,
designing LNPs responsive to stimuli can make their delivery more localized, thus limiting the side
eﬀects. However, the principles and criteria for designing such nanoparticles remain unclear. We
show that the thermodynamic state of the lipid membrane of the nanoparticle is a key design
principle for acoustically responsive fusogenic nanoparticles. We have optimized a cationic LNP
(designated LNPLH) with two diﬀerent phase transitions near physiological conditions for
delivering mRNA. A bicistronic mRNA encoding a single domain intracellular antibody fragment
and green ﬂuorescent protein (GFP) was introduced into a range of human cancer cell types using
LNPLH, and the protein expression was measured via ﬂuorescence corresponding to the GFP
expression. The LNPLH/mRNA complex demonstrated low toxicity and high delivery, which was
signiﬁcantly enhanced when the transfection occurred in the presence of acoustic shock waves. The results suggest that the
thermodynamic state of LNPs provides an important criterion for stimulus responsive fusogenic nanoparticles to deliver
macrodrugs to the inside of cells.
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■ INTRODUCTION
Many human diseases involve abnormal protein−protein
interactions (PPIs) that aﬀect normal biological processes.
Modulation of PPIs is attracting increasing interest in basic and
disease biology. While there are increasing numbers of
examples of successful development of compounds that
interfere with PPI,1 the interaction surface between proteins
are often large and discontinuous, which make conventional
small-molecule inhibitors diﬃcult to isolate. As an alternative
to drug-like compounds, investigations into macromolecules
that speciﬁcally interfere with PPIs have led to some notable
success, for example, with peptides,2 proteins,3,4 and DNA/
RNA/peptide aptamers.5−7 Using such macromolecules (so-
called macrodrugs8) to target PPIs is an approach that builds
on molecular biology rather than chemistry because macro-
drugs are capable of both speciﬁcity and high aﬃnity on target
molecules.
The variable regions of the immunoglobulin heavy chain
(VH) and light chain (VL) are minimal fragments that can
recognize antigens9 and these have been demonstrated to
speciﬁcally bind proteins inside cells and therefore is termed as
iDabs (intracellular domain antibodies).10 The eﬃcacy of
iDabs was shown using an anti-RAS VH single domain.3 RAS
proteins are frequently mutated in human cancers, and
aberrant RAS function leads to constitutive signal transduction
associated with hyper-proliferative and developmental disor-
ders.11 Inhibition of tumor growth by interfering PPIs between
RAS and its interaction partners in vivo using an intracellular
antibody fragment has been shown to be eﬀective in inhibiting
tumor initiation and tumor growth. However, most of the
disease targets, including RAS, are located inside cells, making
it necessary to deliver intracellular antibody fragments as
macrodrugs. This could be achieved using recombinant protein
and nucleic acid coding for the protein. Protein molecules can
be immunogenic, and are generally unstable that makes it
diﬃcult to achieve a therapeutic concentration in vivo. It is
therefore impractical to directly deliver protein molecules
across the plasma membrane into cells.12 Delivering
exogenously produced protein-coding nucleic acid, such as
DNA and mRNA, into cells, to achieve continuous production
of the protein drug in situ is an alternative approach.13,14
However, introducing mRNA, compared to DNA that was
commonly introduced by viral vectors, does not integrate into
host genome because natural degradation pathways of mRNA
also ensure that the protein expression is transient and avoids
unwanted long-term eﬀects. The translation of protein from
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mRNA mostly occurs in the cytoplasm, so delivering mRNA
avoids the need to transport across the nuclear membrane.14
Therefore mRNA delivery will potentially result in a more
eﬃcacious protein expression than via plasmid DNA delivery.
Nonetheless, intracellular nucleic acid delivery remains a
major challenge for large-molecule therapeutics. The scientiﬁc
problems associated with delivering therapeutic mRNA are
fundamentally diﬀerent from the passive intracellular delivery
of small-molecule drugs as the cell membrane selectively
prevents large molecules entering cells. From a thermodynamic
perspective, the energy barrier and the kinetics of crossing the
cellular membrane are related to the size and hydrophilicity of
the molecule.15,16 The energy barrier is higher for larger and
more hydrophilic molecules to such an extent that practically
no mRNA crosses the cellular membrane passively. An added
challenge with mRNA-based therapeutics is that they require
shielding from serum-based degradation and from the immune
system until they are inside the target cells.
Lipid nanoparticles (LNPs) and lipid−nucleic acid-com-
plexed nanoparticles (lipoplexes) can potentially provide
solutions to these problems, both as a safe carrier of the
macrodrug to the target cell and as an agent that forms an
intermediate with the cell membrane delivering the therapeutic
via fusion between LNP and the plasma membrane (Figure
1A,B).17−22 The rate of delivery depends on the energy barrier
that needs to be overcome to form the LNP/cell fusion
intermediate, also known as a stalk, which corresponds to the
lipid membranes deforming from a lamellar Lα phase to an
inverse hexagonal HII phase (see Figure 1B). While stalk-
mediated fusion is a particular example of the endocytosis
mechanism, in general, by making the nanoparticle more
compliant to deformation, its contribution to the activation
energy for internalization can be minimized, which is critical
even for receptor-mediated endocytosis.23 Ultimately, thermo-
dynamic ﬂuctuations or other physical stimuli have to
overcome this barrier to allow the internalization of the
nanoparticle irrespective of the speciﬁc molecular mechanism
involved. Therefore, there are three ways to increase the
probability of the system attaining activation enthalpy of fusion
enhancing nanoparticle uptake; (1) lower the energy barrier,
Figure 1. Physical characteristics of the lipid nanoparticle. (A) Schematic of the LNP−mRNA complex. Amphiphilic lipid molecules are drawn to
show the lamellar ﬂuid phase (Lα) and inverted hexagonal (HII) phase coexistence. mRNA molecules assemble in the intralamellar space of the Lα
phase or the hydrophilic core of the HII phase. When incubated with plasma, a serum albumin corona forms around the shells shielding the positive
charge of the nanoparticle. (B) Intermediate stalk formation during the fusion of two lamellar bilayers is shown take place via the (HII) phase. The
transition occurs via reversible exchange of enthalpy ΔH. (C) Peak intensity in FTIR spectra of the LNP at 2919 cm−1 measured as a function of
temperature. The peak corresponds to the stretching of −CH2 bonds and identiﬁes the gel (Lβ) to ﬂuid (Lα) transition near 37 °C.27 (D) Peak
intensity in FTIR spectra of the LNP at 1468 cm−1 measured as a function of temperature. The peak corresponds to the scissoring of −CH2 bonds
and identiﬁes two kinks corresponding to gel (Lβ) to ﬂuid (Lα) transition near 37 °C and lamellar ﬂuid (Lα) and inverted hexagonal (HII) transition
near 41 °C.27 (E) Zeta potential of LNP/mRNA lipoplex as a function of mRNA titrated reported as the w/w ratio on x axis. The w/w ratio of 0.2
in the vicinity of the isoelectric point was used as initial estimate for the optimum mRNA to LNP ratio (F) size distribution of the lipid
nanoparticles measured using a Zetasizer before and after association with the native mRNA at the w/w ratio of 0.2 (zeta potential 19.1 mV).
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(2) increase the thermodynamic ﬂuctuations, and (3) couple
an external physical stimulus (e.g., acoustic waves), all of which
are employed here. The energy barrier for the fusion
intermediate can be lowered by designing the nanoparticle
close to the Lα → HII transition. The thermodynamic
ﬂuctuations as well as the coupling into acoustic waves are
directly related to the heat capacity of the nanoparticle, which
is maximized near an order−disorder transition (Lα → Lβ).24
Because the system has to operate under the physiological
condition, the aim was to design an LNP/mRNA complex that
has both the transitions near the physiological condition. It has
recently been established how acoustic impulses can induce
state changes in LNPs.24 Our work presents a continuation of
concerted eﬀorts toward establishing a systematic and uniﬁed
thermodynamic approach for localized and enhanced intra-
cellular delivery of macrodrugs using acoustic stimulation. We
combine principles of material science, interface physics,
biophysics, and molecular biology starting from macroscopic
Figure 2. Bicistronic plasmid DNA encoding iDab and green ﬂuorescent protein (EGFP) panel (A) shows the schematic representation of the
expression plasmid and the corresponding in vitro synthesized mRNA encoding the single domain-intracellular antibody fragment (iDab) and
EGFP that are separated by porcine teschovirus-1 2A peptide sequence. The synthesized mRNA has a 5′cap and a 3′ untranslated regions (3′UTR)
before a poly(A) tail of >150 bases. EF-1α Promoter, eukaryotic translation elongation factor 1 alpha 1; BGH pA, bovine growth hormone
polyadenylation signal. Following the transcription of the mRNA and translation, two proteins are made, viz., EGFP and iDab with a P2A tag. The
junction RNA and amino acid sequences are shown in panel (B). The ribosome-skipping site between P2A and EGFP is indicated by the arrow.
Bicistronic plasmid DNA or in vitro transcribed mRNA using native nucleotides were transfected into HEK293T cells using Lipofectamine 2000.
After 24 h, cells were collected and EGFP ﬂuorescence was analyzed by ﬂow cytometry (C) and the protein expression analyzed by western blot
with antibody detecting the P2A tag of the iDab (D) or antibody detecting GFP (E). HEK293T, untransfected HEK293T cells; DNA, cells
transfected with plasmid DNA; mRNA, cells transfected with bicistronic mRNA. The bicistronic mRNA synthesized with pseudo-UPT was
transfected into A549 cells using Lipofectamine 2000. After 7 h incubation, cells were collected and analyzed for the GFP expression by ﬂow
cytometry (F) and lysed and analyzed for the expression level of various protein using western blot (G). Inhibition of phosphorylation of ERK was
determined by the ratio of phospho-ERK to total ERK for each sample (H). A549, untransfected A549 cells; iDab RAS, cell transfected with
bicistronic mRNA iDab RAS-2A-EGFP; iDabmut RAS, cell transfected with bicistronic mRNA iDabmut RAS-2A-EGFP. iDab RAS is an anti-RAS
single-domain intracellular antibody and iDabmut RAS is a mutant form that is expressed but no longer binds to RAS protein.
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eﬀects of the acoustic impulse and how it leads to nanoparticle
internalization. To the best of our knowledge, this is the ﬁrst
instance where acoustic state changes have been employed as a
strategy for macrodrug intracellular delivery. Here, we show
that an EDPPC/cholesterol-based nanoparticle,25 designed to
have both transitions at physiological conditions, is a potent
transfection agent that can eﬃciently deliver a bicistronic
mRNA molecule, encoding an anti-RAS intracellular antibody
fragment, into several diﬀerent mutant RAS-expressing human
cancer cell lines. We further show that these transfected cells
are also susceptible to acoustic treatment using shock waves, as
expected from their thermodynamic state, which results in
signiﬁcant increase in transfection and protein translation of
sensitive cell lines.
■ RESULTS
LNP and Lipoplex Characterization. The ideal lipoplex
for in vivo use will have both the lamellar ﬂuid phase to
inverted hexagonal phase transition (Lα → HII) and lamellar
ﬂuid phase to lamellar gel phase (Lα → Lβ) transition close to
physiological conditions and potentially an external stimulus
can be used to trigger phase transition that will enhance the
fusion of the lipoplex with the cell. A formulation based on
EDPPC and cholesterol (70:30, mol/mol), described
previously,25 has a Lα → Lβ transition at 37 °C and a Lα →
HII transition at 41 °C. The presence of these transitions was
conﬁrmed in our experiment using Fourier-transform infrared
spectroscopy (FTIR) spectra (Figure 1C,D). We have
designated this formulation LNPLH. In addition, two other
formulations were designed: LNP1 to have a strong tendency
to undergo nonlamellar transitions upon mixing with
negatively charged lipids found in cell membranes and LNP2
which has transition temperatures lower than LNPLH, so the
lipids are in the highly ﬂuid state. LNP1 was formulated with
cationic homologues of dilauroyl (EDLPC) and dioleoyl
(EDOPC) lipids, which at a 60:40 composition have been
previously reported to form an inverted micellar cubic phase
upon mixing with the negatively charged lipids, resulting in
enhanced synergistic transfection.26 LNP2 was formulated with
EDPPC and 1,2-dielaidoyl-sn-glycero-3-phosphoe- thanol-
amine (DEPE), which at a 60:40 ratio has a broad Lα → Lβ
transition at 28 °C and a Lα → HII transition at 37 °C.
25
The speciﬁc lipoplex structure that forms when mRNA is
incorporated into the LNPLH was assessed by the zeta potential
of the lipoplex. Figure 1E shows that the zeta potential of the
LNPLH alone (no mRNA) is 50 mV, which is consistent with
the presence of cationic lipids. The LNPLH sample was
prepared from the dried lipid ﬁlm by rehydration and extrusion
as described in the Experimental Section. Concentrated mRNA
was titrated into the LNPLH sample and the zeta potential
monitored as the mRNA/LNPLH ratio increased. The zeta
potential decreases monotonically because of the incorporation
of negatively charged mRNA into positively charged LNP.
There is a relatively sharp drop as the mRNA/LNP ratio
increases from 0.23 to 0.28 at which point the zeta potential
becomes negative and, as the concentration of mRNA is
further increased, the zeta potential continues to decrease
monotonically. The drop around the mRNA/LNP ratio of 0.25
is typical for the internalization of mRNA during the LNP/
mRNA complex formation that follows the accumulation of
mRNA at the LNP surface (for microscopic details of the
process and the intermediate steps20). These experiments gave
an initial estimate for the optimal mRNA to the LNPLH ratio of
20:100 (w/w), and this was further optimized with the use of
cell-based transfection experiments (see below). Figure 1F
shows the size distribution of lipoplex before and after the
association with the native mRNA at the w/w ratio of 0.2 (zeta
potential 19.1 mV), which shows that the mean diameter
increases from 112 to 302 nm and the distribution
polydispersity index increases from 0.254 to 0.334 upon
formation of the lipoplex. The optimal mRNA to LNP ratio
determined in the zeta potential experiments was further tested
with RiboGreen RNA assay and generally more than 95% of
total mRNA in the system was associated with LNP.
The bicistronic mRNA expression used for our study is
illustrated in Figure 2A comprises an mRNA encoding an iDab
and enhanced green ﬂuorescent protein (EGFP), in a
bicistronic format including a 2A peptide derived from porcine
teschovirus-1 (P2A) that allows the iDab and EGFP expressed
simultaneously from one transcript. Figure 2B illustrates the
junction nucleic acid and protein sequences at the end of the
iDab, the P2A, and the start of EGFP. The expression of iDab
from the mRNA is reported by the expression of EGFP, which
can be detected with ﬂuorescence microscopy and ﬂow
cytometry. The bicistronic plasmid DNA was generated by
cloning the iDab-P2A-EGFP expression cassette into a plasmid
that has a human elongation factor-1 alpha (EF-1 alpha)
promoter, and a bovine growth hormone polyadenylation
signal. The iDab-P2A-EGFP was used as a polymerase chain
reaction (PCR) template for in vitro transcription of the
bicistronic mRNA. A modiﬁed version of bicistronic mRNA
was also synthesized with uridine-5′-triphosphate being
replaced with pseudo-uridine-5′-triphosphate (pseudo-UTP)
for an improved stability of the nucleic acid.
Both the plasmid and the naked, native mRNA were
transfected into HEK293T cells (a human embryonic kidney
cell line) using Lipofectamine 2000 and the translation
products were conﬁrmed using ﬂow cytometry of EGFP
ﬂuorescence (Figure 2C) and western blot using antibody
detecting GFP (Figure 2D) or detecting the 2A tag on the
iDab (Figure 2E) 24 h after transfection. While there are
reports of ineﬃcient ribosome recognition of the 2A skipping
sequence,28 in this case, very little iDab-EGFP fusion protein
was observed (Figure 2D). It was also noted that transfection
with the plasmid DNA was only about 30% of cells, while
almost all cells transfected with mRNA showed the EGFP
expression (Figure 2C). However, the levels of GFP
ﬂuorescence were higher in the plasmid transfection than
mRNA. Both an anti-RAS VH iDab (iDab RAS) and a mutant
form of anti-RAS VH iDab (iDabmut RAS) that has only three
amino acids mutated from iDab RAS but no longer binds to
RAS protein3 was also constructed to the bicistronic expression
system. Human lung adenocarcinoma cell line A549 that
harbor a homozygous KRASG12S allele was used to test the
iDab RAS and iDabmut RAS. The modiﬁed version of both
bicistronic mRNAs was introduced into A549 cells and the
expression of the iDab RAS and iDabmut RAS was ﬁrst
indicated by the expression of EGFP (Figure 2F) and
conﬁrmed using western blot (Figure 2G). The persistent
stimulation of the MAPK/ERK signal pathway, caused by the
constitutive activation of mutant KRAS in A549 cells, was
eﬃciently inhibited by iDab RAS, expressed from the
introduced bicistronic mRNA, by 5-fold compared to the
mutant form iDabmut RAS that did not show inhibition of the
Ras-dependent pathway (Figure 2H). This showed that there
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was suﬃcient intracellular antibody expression to interfere with
the RAS-eﬀector PPI.
Assessment of mRNA Delivery to Human Cells Using
LNP1, LNP2, and LNPLH. All three LNP formulations were
tested for delivery of a ﬂuorescently labeled mRNA lacking a
polyA tail, which was synthesized in vitro using ﬂuorescein-12-
UTP instead of native UTP, into HEK293T cells. The
ﬂuorescent signals in the FITC channel from cells delivered
with mRNA by diﬀerent LNP formulations were compared
using confocal microscopy and ﬂuorescence-activated ﬂow
cytometry (FACS). The formulations delivered the ﬂuorescent
mRNA into HEK293T cells at diﬀerent eﬃciencies (Figure S1,
Supporting Information) with LNPLH that has both Lα → Lβ
and Lα → HII transitions close to physiological conditions,
showing higher eﬃciency than LNP1 or LNP2.
Variable Cellular Uptake and mRNA Delivery by
LNPLH. The most eﬃcient lipoplex appeared to be LNPLH and
therefore this formulation was used for subsequent experi-
ments. Initial experiments of zeta potential measurements of
mRNA titrations with the LNPLH-suggested association with
the mRNA synthesized using native nucleotides were optimal
at the mRNA to the LNPLH ratio of 20:100 (w/w) (Figure
1E). This loading ratio was optimized for the best transfection
by transfecting HEK293T cells using the same amount of
mRNA complexed with LNP at various mRNA to LNP ratios
from 2:100 to 20:100 (w/w). The result showed that the
transfection levels appear to saturate at an mRNA to LNP ratio
of 16:100 and 20:100 (w/w) (Figure 3) and a ratio of 20:100
was used in subsequent experiments.
The mRNA was protected by the encapsulation in the
LNPLH and the stability of the mRNA within the lipoplex was
conﬁrmed after recovery from prepared particles (Figure S2,
Supporting Information). Further protection for the mRNA
was achieved by the use of a modiﬁcation in which uridine-5′-
triphosphate was replaced with pseudo-UTP, known to
increase the nuclease stability and enhance mRNA translation
while showing innate immune suppression.29 The antireverse
cap analog (ARCA) was also used to improve translatable
mRNA yield and to achieve better transfection eﬃciency. We
observed that the modiﬁed mRNA gave rise to higher
ﬂuorescence when transfected in A549 cells (Figure S3A,
Supporting Information) and mRNA was released and
expressed from both LNPLH and Lipofectamine 2000 (Figure
S3B, Supporting Information).
The ability of the LNPLH lipoplex to deliver mRNA and
release it for translation into protein was assessed with an array
of human cell lines, derived from diﬀerent cancer types, using
an LNP to mRNA ratio of 20:100 (w/w). The translation of
the mRNA following delivery by the LNPLH was quantiﬁed by
the ﬂuorescent signal from the EGFP expression, compared to
transfection with commercially available Lipofectamine 2000.
The transfected cells were incubated for 24 h before analyzing
using ﬂow cytometry and the transfection level, which is
represented by the gated GFP-positive cell population was
normalized to the low background, auto-ﬂuorescence signal
(∼1%) from the untransfected cells. HEK293T cells trans-
fected with mRNA using Lipofectamine 2000, as the positive
control, displayed about 92% of the viable cells with the EGFP
expression. Figure 4 shows the results for 14 cell lines,
Figure 3. Optimization of the mRNA to LNP ratio for lipoplex production. LNPLH was complexed with mRNA at the diﬀerent weight ratios
indicated from 2:100 to 20:100 mRNA/LNP and were compared by transfection in HEK293T cells. Transfection levels were assessed by ﬂow
cytometry and are represented as the percentage of cells showing GFP ﬂuorescence (upper panel). Representative ﬂow cytometry results of the
indicated mRNA/LNPLH ratios were indicated with arrows and shown in the lower panel.
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including HEK293T cells. In the main, we observed best
transfection eﬃciency with the commercial transfection
reagent (although toxicity was also much higher, see below).
However, the LNPLH/mRNA complex signiﬁcantly delivered
mRNA that could be translated into the reporter EGFP protein
in eleven of the fourteen cell lines tested, with four cell lines
A549, HT1080, DU145, and PSN1 exhibiting greater than
20% delivery. There were three cell lines that did not result in
enhanced delivery: DLD1 (colorectal), SW480 (colorectal),
and HCC4006 (lung). With the possible exception of
colorectal cancer lines, there was no obvious cell type bias
mRNA delivery. However, some cell lines show high LNPLH
delivery of the mRNA that may indicate properties yet to be
elucidated that can be exploited for increasing cargo release.
The toxicity of the LNPLH/mRNA complex was investigated
using CellTiter-Glo luminescent cell viability assay on the two
cell lines (A549 and HT1080) that displayed the highest levels
of the GFP expression after transfection. Cells were incubated
with the LNPLH/mRNA complex for 24 h before the cell
viability was determined. The viability of A549 and HT1080
cells that were transfected with LNP/mRNA was not
signiﬁcantly reduced compared with the viability after mRNA
transfection using Lipofectamine 2000, in which A549 viability
was 14% after 24 h and HT1080 viability was 1.5% after 24 h
(Figure 5). Cells were usually assayed for protein translation
24 h after transfection; however, it was also noticed that the
cell viability and morphology were not signiﬁcantly aﬀected
even after 72 h after treatment (data not shown). Thus,
although Lipofectamine 2000 generally resulted in better
translatable mRNA delivery than the LNPLH/mRNA, it also
resulted in a much smaller number of viable cells.
Shock Waves Promote the mRNA Delivery Using
LNPLH. The ability of LNPs to deliver nucleic acids to cells and
release their cargo for transcription/translation is an important
objective. One goal of this work is to develop ways to enhance
mRNA delivery and release in order to impart a therapeutic
function to these macrodrugs. The use of pressure waves such
as shock waves is one possible method to inﬂuence cell
structure and LNP conformational state that might facilitate
macrodrug release, but this may have deleterious eﬀect of cell
viability. The eﬀect of shock waves on viability was investigated
with A549 and HT1080 cell lines. Immediately after LNPLH/
mRNA transfection, 500 shock waves were delivered at energy
setting P10 (see Experimental Section), and cell viability was
compared with LNPLH/mRNA transfected cells that were not
treated with shock waves. Cells that were treated with shock
waves after transfection by LNPLH showed minimal loss of
viability (10% for A549 or 23% for HT1080). This compares
favorably with loss of viability observed when using Lipofect-
amine 2000, where loss of viability ranged from 86% to 98%
(Figure 5).
The most likely mechanisms by which shock waves interact
with lipid membranes is either through direct stress or through
cavitation. Therefore, we employed diﬀerent energy level
settings and diﬀerent doses of shock waves to determine the
optimal combination. Accordingly, we transfected the A549,
HT1080, HEK293T, and PSN1 (all which had exhibited good
transfectability, Figure 4) using setting P5, that is, below the
cavitation threshold in this experimental system and P10, that
is, above the cavitation threshold (see Experimental Section)
with diﬀerent doses of shock waves. Transfection was analyzed
after 24 h by monitoring the EGFP expression from the LNPLH
cargo mRNA (Figure 6A). When shock waves were applied, we
observed an increased percentage of cells showing the GFP
signal compared to no shock waves. We also noted a marked
shift in the population toward higher ﬂuorescence intensity in
the presence of LNPLH lipoplex, which is further quantiﬁed
with median ﬂuorescence intensity (MFI) in the presence or
absence of shock waves, for all four cell lines. The eﬀect is most
prominent in HEK293T cells, followed by A549, PSN1, and
HT1080. Thus, exposure to shock waves improves the
population of cells showing the EGFP expression. However,
the peak signal itself is not aﬀected signiﬁcantly by the shock
waves, implying that the peak intensity is probably limited by
the rate of translation and not the delivery (discussed below).
Figure 4. LNPLH transfection of a human cancer cell line panel with
the bicistronic mRNA LNPLH/mRNA complex was prepared using
the 20:100 w/w ratio of mRNA/LNP and used to transfect lung
cancer cell lines (A549, H1650, HCC827, H1975, and HCC4006), a
ﬁbrosarcoma cell line (HT1080), prostate cancer cell lines (PC3 and
DU145), colorectal cell lines (DLD1 and SW480), a Ewing Sarcoma
cell line (A673), a breast cancer cell line (SKBR3), a pancreatic
cancer cell line (PSN1), and embryonic kidney cells HEK293T. The
percentage of cells with GFP ﬂuorescence was analyzed using ﬂow
cytometry and the values converted to percentages of the maximum
count using FlwoJo software as shown in the histograms. Lipofect-
amine 2000 was used as control for mRNA transfection. Data shown
as mean values ± standard deviation of 3 or more samples.
Figure 5. Eﬀect of LNPs on cell viability. Two cell lines (A549 and
HT1080) were transfected by mRNA using either LNPLH or
Lipofectamine 2000 and cell viabilities were analyzed using
CellTiter-Glo Luminescent Cell Viability Assay at 24 h after
transfection. Alternatively, 500 shock waves (energy setting P10 of
a Swiss PiezoClast) were applied to cells after LNPLH/mRNA
complex had been added to the cultures and cells incubated for 24 h
before cell viability assay. SW, samples exposed to shock wave; no
SW, samples without shockwave treatment. Data are shown as mean
values ± standard deviation of 3 or more samples.
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Figure 6B plots average expression levels obtained using
diﬀerent shock wave settings, showing that both an increase in
the energy level as well as the number of shock waves increases
the eﬃciency of the process.
■ DISCUSSION
Intracellular Delivery of mRNA Using LNPLH. The
implementation of macromolecule drugs (deﬁned as macro-
drugs8 as opposed to small-molecule drugs) for intracellular
therapy has enormous implications because of the range of
molecules (nucleic acids and proteins) that can be selected and
optimized by molecular biology techniques. However, the
challenges of delivering macrodrugs to cells continue to
impede progress. There are at least two strategic issues. One is
the vehicle of choice and the other is the macromolecule cargo.
In the work presented here, we have developed an LNP as the
vehicle and modiﬁed mRNA as the macrodrug. As proof-of-
concept, we made a bicistronic mRNA coding for an
intracellular antibody fragment that binds to KRAS3 and an
EGFP separated by 2A peptide derived from porcine
teschovirus-1.30 We conﬁrmed that our in vitro synthesized
mRNA was functional by transfecting into A549 cells and
detecting GFP ﬂuorescence by ﬂow cytometry, which means
that mRNA is released from the LNPs and protein synthesis
occurs in the cells (Figure 2F). Further, we compared the
eﬀect of the anti-RAS iDab with a mutant version, that has only
3 amino acid changes compared to iDab RAS but does not
bind to KRAS. While the EGFP that was expressed from
Figure 6. Shock waves improve the delivery of mRNA to cells by LNPLH. The mRNA was delivered to four human cell lines (HEK293T, A549,
HT1080 and PSN1) with LNPLH/mRNA lipoplex with or without shock wave treatment and the GFP ﬂuorescence was measured by ﬂow
cytometry after 24 h. Representative FACS overlay plots of GFP signals from cells transfected with lipoplex and treated with shock waves at
indicated settings (grey area) were compared with lipoplex transfected cells without shock waves treatment (solid line) are showed in panel (A). In
panel (B), all four cell lines were transfected with lipoplex and treated with various settings of shock waves as indicated. The expression levels of
GFP after each treatment were represented using relative MFI by subtracting the MFI of the untreated samples (UN). UN, untransfected; Lipoplex,
mRNA was delivered into cells using lipoplex SW, samples exposed to shock waves; no SW, samples without shockwave treatment. Data shown as
mean values ± standard deviation of 3 or more samples.
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mRNA of both the antibody fragments (Figure 2F), only the
iDab RAS mRNA protein product was able to inhibit the
phosphorylation of the ERK biomarker downstream of KRAS
signaling (Figure 2G,H).
Intracellular delivery of nucleic acid using viral systems is
often limited by unwanted immune responses, but nonviral
materials, such as lipid-based nanoparticles (LNP) and
polymer-based materials, have been developed to evade
antigenicity.31−34 Some of these nanomaterials are at the
stage of clinical trials to deliver siRNA35 and mRNA.36
Nonetheless, the identiﬁcation of eﬀective and safe delivery
systems remains one of the biggest challenges for intracellular
mRNA delivery.
The delivery of nucleic acid using cationic lipids is generally
nonspeciﬁc but still a wide variety of cells are diﬃcult to
transfect probably because of the individual physical properties
and composition of the phospholipid membranes. We have
employed knowledge of the thermodynamics of lipid
membranes25 to identify the formulation of EDPPC/
cholesterol (LNPLH) that has two phase transitions, Lα → Lβ
and Lα → HII, close to body temperature (Figure 1), from
which we designed an LNP/mRNA complex optimized for
entry into target cells and could be triggered by shock waves.
Even in the absence of shock waves, the presence of these
fusion-facilitating transitions exhibited transfection activity
comparable to that of Lipofectamine 2000 in a number of
cell lines (Figure 4). Using shock waves resulted in enhanced
delivery in HEK293T, A549, and PSN1 cells but not in
HT1080 cells (Figure 6). These results suggest that the LNPLH
formulation may need to be tuned for speciﬁc cell targets.37
For therapeutic applications, additional lipids (e.g., PEGylated
lipids) are usually required to improve the delivery of the LNP,
therefore the ratios of each component may also need to be
adjusted accordingly to keep both phase transitions close to
the physiological conditions when designing the multi-
component LNP.
Challenges in mRNA Delivery Using LNPLH. The
mRNA was protected by encapsulating with the LNPLH
(depicted in Figure 1A). Although a comparable percentage
of cells showed protein expression when the mRNA was
introduced by both LNPLH and Lipofectamine 2000 (Figure
4), the expression level of protein in cells with mRNA
delivered by LNPLH is still lower than those transfected with
Lipofectamine 2000 (Figure S3, Supporting Information).
Therefore, the iDab translated from LNPLH-mediated mRNA
delivery was not suﬃcient to show signiﬁcant inhibition on the
RAS-dependent signaling pathway, unlike Lipofectamine 2000
(Figure 2G). It is noted that when modiﬁed mRNA was
incorporated into the LNP, the diﬀerence in transfection was
minor (Figure S3, Supporting Information) suggesting that the
limiting steps for the protein expression from LNPLH-mediated
mRNA delivery could be the endosomal escape of the lipoplex
and/or the release of the mRNA from the lipoplex. The phase
transition of LNPLH triggered by shock waves could enhance
the fusion of the lipoplex with both the cell membrane and the
endosome membrane; therefore, a higher percentage of cells
with mRNA delivered by LNPLH showed improved protein
expression when shock waves were applied (Figure 6).
However, it should be noted that the peak of the GFP signal
intensity was about 10-fold weaker for the mRNA delivered
with LNPLH compared to the same cell types that were
transfected with modiﬁed mRNA using Lipofectamine 2000
(Figure S3, Supporting Information). This is presumably
because LNPLH protects mRNA from degradation but also
hinders ribosome access to mRNA. Therefore, the kinetics of
release of mRNA from LNPLH is a parameter that could be
improved to achieve better protein synthesis. This may also
explain the second peak (or a tail) of the stronger GFP signal,
comparable with mRNA transfected by Lipofectamine 2000,
evident when the lipoplex (modiﬁed mRNA/LNPLH) to cell
ratio was increased (Figure S3B, Supporting Information).
However, the above interpretation assumes GFP ﬂuorescence
is directly proportional to protein expression, which is only a
ﬁrst order approximation.38
A main goal of this study was to demonstrate that the
acoustic control of the state of a liposome can aﬀect its
transfection eﬃciency and to explore a new method to improve
the mRNA delivery across the cell membrane utilizing the
external stimulus. The propensity of LNPLH to undergo both
Lα → Lβ and Lα → HII transitions after small perturbations,
together with its signiﬁcant activity in HEK293T cells even in
the absence of shockwaves, makes LNPLH a promising
candidate for acoustic control of transfection activity. While
the proximity to Lα→ Lβ and Lα→ HII transitions in the initial
state diagram of the LNPLH makes it very likely that these
transitions, and hence transfection, occur upon the interaction
of LNPLH with various cell lines and shock waves, the presence
of these transitions in the initial state diagram is not necessary
and such transition can emerge from the interaction of the cells
and the LNP itself. In fact, LNP1 has previously been shown to
induce such synergistic transitions upon interaction with
negatively charged lipids. However, such transitions cannot
be predicted without a comprehensive biophysical under-
standing of such synergistic interactions with native cellular
membrane, especially in the presence of shock waves, which is
beyond the scope of this work. Given the complexity of cellular
membranes that is challenging to mimic artiﬁcially, a
systematic approach will require a proper access to the
thermodynamic state of the cellular membrane during such
interactions, which remains experimentally challenging. There-
fore, LNPLH is not necessarily the most optimal solution but an
important starting formulation for our perturbation-based
approach. The expression level of protein depends not only on
the amount of mRNA that entered the cells but also other
factors including endosome release39 and translational
regulation in each cell type. In this experiment, the protein
was detectable suggesting the mRNA was successfully
delivered across the cell membrane and released into the
cytoplasm while the cell viability was not aﬀected compared to
the lipofectamine 2000 system. The LNP could potentially be
equipped with functional lipids such as ionizable lipids40 to
promote the intracellular release, biodegradable lipids to
improve biocompatibility, and PEGylated lipids to improve
the pharmacokinetics and pharmacodynamics of the LNP for
future in vivo use. Furthermore, immuno-LNP with antibody
against cell-speciﬁc surface marker conjugated to the LNP
would allow the LNP/mRNA lipoplex to localize to target sites
and facilitate the targeted delivery of mRNA to speciﬁc cell
types for therapeutic applications.
■ CONCLUSIONS
Our work has highlighted the importance of the thermody-
namic state of the lipid interface as a design principle for
nanoparticles, in particular, that having the interfacial-lipids
close to two-phase transitions enhances intracellular delivery
through both passive endocytosis and ampliﬁcation of coupling
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to an external stimulus. This is important because the focus is
usually on the molecular structure of the various constituents
of the nanoparticles, with limited attention to the thermody-
namic state. This work has demonstrated that thermodynami-
cally designed LNPs can deliver mRNA to various types of
cancer cells in vitro and that the delivery eﬃciency is
signiﬁcantly enhanced in the presence of shock waves. The
transfection eﬃciency was dependent on the cell type when the
LNPLH formulation was employed and therefore it may be that
a better understanding of cellular biophysics (i.e., the role of
cell membrane composition and physical selectivity due to
inherent nonlinearity of phase transitions) will allow the design
of LNPs that are selective for predetermined cell types. In
many clinical applications, this could be a beneﬁt for the design
of cell-selective LNPs that would result in reduced oﬀ target
delivery.
■ EXPERIMENTAL SECTION
Preparation and Characterization of LNP. The 1,2-dipalmi-
toyl-sn-glycero-3-ethylphosphocholine (EDPPC) in chloroform
(Avanti Polar Lipids 890702), 1,2-dilauroyl-sn-glycero-3-ethylphos-
phocholine (EDLPC, Avanti Polar Lipids 890700), 1,2-dioleoyl-sn-
glycerol-3-ethylphosphocholine (EDOPC, Avanti Polar Lipids
890704), 1,2-dielaidoyl-sn-glycerol-3-phosphoethanolamine (DEPE,
Avanti Polar Lipids 850726), cholesterol (Sigma-Aldrich C8667-5G)
and chloroform (ACROS Organics 364321000) were purchased and
used without further puriﬁcation. LNP1 was formed using 60:40
EDLPC/EDOPC mol ratio, LNP2 was prepared using EDPPC/
DPPE at a 60:40 mol ratio, LNPLH was prepared using EDPPC and
cholesterol at a 70:30 mol %. Lipids of each formulations were mixed
in chloroform and dried either at room temperature in a glass vial
overnight in a tissue culture hood or at 42 °C for 2 h using a rotary
evaporator. The subsequent lipid ﬁlm was hydrated with 1 mL of
RNAse-free water (Thermo Fisher Scientiﬁc 10977035) at 60 °C
followed by vortexing and extrusion through a 400 nm polycarbonate
ﬁlter (Avanti mini-extruder set) at 50 °C.
The FTIR spectrum was obtained using the attenuated total
internal reﬂectance (Bio-rad spectrometer, FTS6000). The surface of
the sensing prism was covered with the LNPLH emulsion at the
concentration of 1.2 mg/mL and was covered by the temperature-
controlling apparatus from top. Absorption spectra were recorded
from wave numbers 400−4000 cm−1, with a resolution of 2 cm−1.
Absorption spectra of RNAse-free water were linearly subtracted as
the background signal. The size and zeta potential of LNPLH and the
lipoplex were characterized using diﬀerential light scattering (Malvern
Panalytical, Zeta Sizer). The LNPLH sample was prepared by diluting
40 μL of the LNPLH emulsion at the stock concentration of 1.2 mg/
mL into 800 μL of RNAse-free water. To make the lipoplex, mRNA
(252 ng/μL) was titrated in to the LNPLH emulsion at 25 °C and the
zeta potential was measured for every 10 μL of mRNA added. The
sizes were measured for pure LNPLH and for lipoplex at the optimized
mRNA to LNPLH ratio (0.2 w/w). Samples were measured
immediately after the addition of mRNA at 25 °C.
Construction of the Bicistronic Plasmid. Cloning was made
using the VHExpress vector (Bradbury, Gene 1997)41 to replace the
VH expression cassette of the original vector between PmlI and XbaI
recognition sites by a multiple cloning site consists PmlI, NheI, PacI,
NotI, BglII, and XbaI recognition sites. The sequence of the multiple
cloning sites is CACGTGGCCAGCTAGCCCTGCAGGTTAAT-
TAAGCGATCGCGGCGCGCCACTAGTGCGGCCGA-
GATCTTCTAGA. The resulting construct was termed pJEF vector.
The EGFP coding sequence was PCR-ampliﬁed from the vector pEPI
(a gift from Wade-Martins, University of Oxford, UK)42 using the
forward primer 5′-AATTGCTAGCCTCGAGGGATCCTCTA-
GAGCGGCCGCAATGGTGAGCAAGGGCGAG-3′ and the reverse
primer 5′-TTATTTAGATCTGAGTCCGGACTTGTAC-3′ and
cloned into the pJEF vector between NotI and BglII recognition
sites to construct the pJEF-EGFP vector. The bicistronic expression
cassette iDab-P2A-EGFP for both iDab RAS and iDabmut RAS was
designed to include the T7 promoter followed by N-terminal
farnesylation sequence to the 5′ end. The forward primer for PCR
ampliﬁcation of iDab-P2A was 5′-ACCATTTTAATTAATAATAC-
GACTCACTATAGGGGAGCTCGAATTCACTAGTGCCGCCAC-
CATGCTGTGCTGTATGAGAAGAACCAAACAGGTTGCC-
GAGGTGCAGCTG-3′ and the reverse primer was 5′-AC-
CATTGCGGCCGCGTCGACGGATCCAAGCTTAGGTC-
CAGGGTTCTCCTCCACGTCTCCAGCCTGCTTCAG-
CAGGCTGAAGTTAGTAGCGCTCGAGACGGTGAC-3′.
The PCR product of iDab-P2A was cloned using PacI/NotI sites of
the pJEF-EGFP vector to produce the bicistronic plasmid pJEF-iDab-
2A-EGFP. The iDabs used in this study are anti-RAS VH and its
inactivated mutant version.3
mRNA Synthesis. The iDab-P2A-EGFP fragment was PCR-
ampliﬁed using forward primer 5′-GGGTTTTATGCGATG-
GAGTTTC-3′ and reverse primer 5′-AAGAAAGCGAAAG-
GAGCG-3′ from the pJEF-iDab-2A-2EGP plasmid. The PCR
products were used for mRNA synthesis. The mMESSAGE
mMACHINE Kit (Invitrogen AM1344) was used for in vitro
transcription using native NTPs. The MEGAscript T7 Transcription
Kit (Invitrogen AM1333) was used for mRNA synthesis using ARCA
(NEB S1411S) and pseudo-UTP (Jena Bioscience NU-1139S) with a
modiﬁed protocol. The reaction (1 μg of PCR product, 7.5 mM of
ATP, CTP, and pseudo-UTP, 1.5 mM of GTP, 6 mM of ARCA, 2 μL
of 10× reaction buﬀer and 2 μL of enzyme mix) was diluted to 20 μL
of the ﬁnal volume with nuclease-free water and incubated at 37 °C
for 4 h followed by TURBO DNase (ﬁnal concentration of 2 U/μL)
treatment at 37 °C for 15 min. A poly(A) tail was added to the
synthesized mRNA using a poly(A) Tailing Kit (Invitrogen AM1350).
The ﬂuorescently labeled mRNA was also synthesized with the
MEGAscript T7 Transcription Kit following the steps described
above except the 10× concentrated Fluorescein RNA Labeling Mix
(ROCHE 11685619910) was used as the NTP mixture. The
ﬂuorescently labeled mRNA was synthesized without poly(A) tailing.
Synthesized mRNA was puriﬁed using RNeasy Plus Mini Kit (Qiagen
74134) and the concentration was measured using NanoDrop ND-
8000.
RiboGreen RNA Assay. The mRNA was quantitated using the
Quant-iT RiboGreen RNA Reagent (Invitrogen R11490). LNP/
mRNA lipoplex was diluted in TE buﬀer or the same volume of TE
buﬀer containing 1% of Triton X-100 (Triton buﬀer). The free
mRNA in the system that was not incorporated with the LNP was
quantitated from the sample in TE buﬀer. The total mRNA of both
incorporated and free mRNA in the system was quantitated from the
sample in Triton buﬀer. The mRNA associated with the LNP was
calculated by subtracting the free mRNA (mRNA detected from the
sample diluted in TE buﬀer) from the total mRNA (mRNA detected
from the sample diluted in Triton buﬀer).
Cells Lines and Tissue Culture. Lung cancer cell lines A549,
H1650, HCC827, H1975, and HCC4006, ﬁbrosarcoma cell line
HT1080, prostate cancer cell lines PC3 and DU145, colorectal cell
lines DLD1 and SW480, Ewing sarcoma cell line A673, breast cancer
cell line SKBR3, pancreatic cancer cell line PSN1, and HEK293T cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(Gibco 31966-021) medium supplemented with 10% FBS (Sigma
F7524) and penicillin streptomycin (Gibco 15140-122).
Transfection, Flow Cytometry, and Confocal Microscopy.
The stock LNPLH (1.2 mg/mL) was diluted 5 times with Opti-MEM
(Thermo Fisher Scientiﬁc 31985070) to prepare the LNPLH working
solution. The Lipofectamine 2000 transfection reagent (Thermo
Fisher Scientiﬁc 11668027) was prepared by diluting 3 μL of stock
solution into 50 μL of Opti-MEM. The mRNA was prepared at 50
ng/μL with Opti-MEM and either the LNPLH working solution or the
Lipofectamine 2000 transfection reagent were mixed with an equal
volume of diluted mRNA to yield the LNP/mRNA or Lipofectamine
2000/mRNA complexes. Cells cultured in a T75 ﬂask was detached
with trypsin before transfection and prepared at 300 000 cells/mL in
DMEM with 10% FBS. Each 250 μL of cell suspension was mixed
with 30 μL of LNP/mRNA or Lipofectamine 2000/mRNA complex
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in a thin-walled tube and treated with or without shockwave at 37 °C.
Transfected cells were transferred to 48-well plates and incubated for
24 h before ﬂow cytometry analysis using Attune NxT ﬂow cytometer
(Thermo Fisher Scientiﬁc) using a forward scatter (FSC-area)/side
scatter (SSC-area) plot for gating live cells followed by an FSC-
height/FSC-area plot for doublet discrimination. The GFP-positive
population was gated on the single-cell population terming 1% of the
GFP signal from the background in the negative control
(untransfected cells).
Viability Assays. Cell viability was measured using CellTiter-Glo
cell viability assay (Promega G7573). Cells were cultured in 96-well
plates and, after transfection, were incubated for 24 h, the medium
was removed and 100 μL of the CellTiter-Glo reagent was added to
each well and mixed by gentle shaking. The plate was incubated at
room temperature for 10 min and the luminescence recorded using a
plate reader (PerkinElmer, 2103 Envision).
Western Blot Analysis. Cells were transfected with DNA or
mRNA and, after 6 h of incubation, were detached with trypsin
(Gibco 25300054), washed with PBS, and lysed with lysis buﬀer 10
mM Tris (pH 8), 1% (w/v) SDS, 1% (v/v) protease inhibitor
(Millipore 535140), and 1% (v/v) phosphatase inhibitor (Thermo
Fisher Scientiﬁc 78402) following with sonication using Diagenode
Bioruptor Pico with settings of 30 s on, 30 s oﬀ, 10 cycles at 4 °C. The
protein concentration of the whole lysate was measured using the
BCA protein assay kit (Thermo Fisher Scientiﬁc 23225), and 15 μg of
the total protein for each sample was separated by SDS-PAGE,
transferred to poly(vinylidene diﬂuoride) membrane; proteins were
detected by western analysis with the antibodies below and visualized
using an electrochemical luminescence (ECL) detection kit (Thermo
Fisher Scientiﬁc 34079). Antibodies used were anti-2A (Millipore
ABS31), anti-GFP (Santa Cruz sc-9996), and anti-phospho-Erk1/2
(Cell Signaling 9101S) as primary antibodies for the expression of
iDab and EGFP and endogenous phosphorylated Erk1/2. Total Erk1/
2 and cyclophilin B were detected using anti-Erk1/2 (Cell Signaling
9102S) and anti-cyclophilin B (Abcam, ab178397). HRP-conjugated
anti-rabbit IgG (Cell Signaling 7074S) or anti-mouse IgG (Cell
Signaling 7076S) were used as the secondary antibody for ECL
detection.
Shock Waves. Shock waves were applied to the samples in thin-
wall PCR tubes (Starlab I1402-2908). The cap of the PCR tubes was
further sealed by wrapping paraﬁlm wax around and was placed at the
focus of the shockwave source in a temperature-controlled water tank
at 37 °C. Shock waves were generated by a Swiss PiezoClast (EMS
Electro Medical Systems S.A, Switzerland) and ﬁred in to the water
tank from below and focused at 1 cm below the free surface.24 The
amplitude of the shock waves was controlled via energy level setting,
which could be varied from P1 to P20. The focal waveforms consisted
of a pulse about 5 μs in duration with a leading positive phase and
trailing negative phase. At P5, the peak pressure amplitudes were 1.3
MPa for both phases and at P10 the peak pressure amplitudes was 2
MPa for the positive phase and 1.5 MPa for the negative phase.43 A
ﬁxed number of shockwaves were ﬁred at a repetition rate of 3 Hz into
one sample at a time. During this time, the rest of the samples were
kept at 37 °C.
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Elimination of Large Tumors in Mice by mRNA-Encoded Bispecific
Antibodies. Nat. Med. 2017, 23, 1241.
(32) Kaczmarek, J. C.; Patel, A. K.; Kauffman, K. J.; Fenton, O. S.;
Webber, M. J.; Heartlein, M. W.; DeRosa, F.; Anderson, D. G.
Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the
Lungs. Angew. Chem. Int. Ed. 2016, 55, 13808−13812.
(33) Miller, J. B.; Zhang, S.; Kos, P.; Xiong, H.; Zhou, K.; Perelman,
S. S.; Zhu, H.; Siegwart, D. J. Non-Viral Crispr/Cas Gene Editing in
vitro and in vivo Enabled by Synthetic Nanoparticle Co-Delivery of
Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed. 2017, 56, 1059−
1063.
(34) Ball, R. L.; Hajj, K. A.; Vizelman, J.; Bajaj, P.; Whitehead, K. A.
Lipid Nanoparticle Formulations for Enhanced Co-Delivery of siRNA
and mRNA. Nano Lett. 2018, 18, 3814−3822.
(35) Behlke, M. A. Progress Towards in vivo Use of siRNAs. Mol.
Ther. 2006, 13, 644−670.
(36) Richner, J. M.; Himansu, S.; Dowd, K. A.; Butler, S. L.; Salazar,
V.; Fox, J. M.; Julander, J. G.; Tang, W. W.; Shresta, S.; Pierson, T. C.;
Ciaramella, G.; Diamond, M. S. Modified mRNA Vaccines Protect
against Zika Virus Infection. Cell 2017, 168, 1114−1125 e10.
(37) Otto, O.; Rosendahl, P.; Mietke, A.; Golfier, S.; Herold, C.;
Klaue, D.; Girardo, S.; Pagliara, S.; Ekpenyong, A.; Jacobi, A.; Wobus,
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